MX2023008746A - Forma morfica ventajosa de la sal de hemi-sulfato de at-527. - Google Patents
Forma morfica ventajosa de la sal de hemi-sulfato de at-527.Info
- Publication number
- MX2023008746A MX2023008746A MX2023008746A MX2023008746A MX2023008746A MX 2023008746 A MX2023008746 A MX 2023008746A MX 2023008746 A MX2023008746 A MX 2023008746A MX 2023008746 A MX2023008746 A MX 2023008746A MX 2023008746 A MX2023008746 A MX 2023008746A
- Authority
- MX
- Mexico
- Prior art keywords
- hemi
- sulfate salt
- advantageous
- morphic form
- efficacy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D9/00—Crystallisation
- B01D9/0004—Crystallisation cooling by heat exchange
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Thermal Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163141789P | 2021-01-26 | 2021-01-26 | |
| PCT/US2022/013953 WO2022164941A1 (en) | 2021-01-26 | 2022-01-26 | Advantageous morphic form of at-527 hemi-sulfate salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023008746A true MX2023008746A (es) | 2023-08-01 |
Family
ID=82653876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023008746A MX2023008746A (es) | 2021-01-26 | 2022-01-26 | Forma morfica ventajosa de la sal de hemi-sulfato de at-527. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20230365611A1 (https=) |
| EP (1) | EP4284389A4 (https=) |
| JP (1) | JP2024504392A (https=) |
| KR (1) | KR20230135635A (https=) |
| CN (1) | CN116744939A (https=) |
| AU (1) | AU2022213335A1 (https=) |
| BR (1) | BR112023014825A2 (https=) |
| CA (1) | CA3173656A1 (https=) |
| IL (1) | IL304402A (https=) |
| MX (1) | MX2023008746A (https=) |
| TW (1) | TW202245806A (https=) |
| WO (1) | WO2022164941A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL288737B (en) | 2017-02-01 | 2022-09-01 | Atea Pharmaceuticals Inc | Hemisulfate nucleotide salt for treatment of hepatitis c virus |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| AU2022213335A1 (en) * | 2021-01-26 | 2023-07-27 | Atea Pharmaceuticals, Inc. | Advantageous morphic form of at-527 hemi-sulfate salt |
| IL308921A (en) | 2021-06-17 | 2024-01-01 | Atea Pharmaceuticals Inc | Combination anti-HCV therapy is beneficial |
| WO2024211746A1 (en) * | 2023-04-06 | 2024-10-10 | Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center | Treatment of autoimmune diseases and cancer with protease inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3182565A1 (en) | 2015-03-06 | 2016-09-15 | Atea Pharmaceuticals, Inc. | .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment |
| WO2018048937A1 (en) | 2016-09-07 | 2018-03-15 | Atea Pharmaceuticals, Inc. | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment |
| US20180214370A1 (en) * | 2017-01-31 | 2018-08-02 | L'oreal | Topcoat for long-wear lip compositions |
| IL288737B (en) | 2017-02-01 | 2022-09-01 | Atea Pharmaceuticals Inc | Hemisulfate nucleotide salt for treatment of hepatitis c virus |
| EP3773753A4 (en) | 2018-04-10 | 2021-12-22 | ATEA Pharmaceuticals, Inc. | TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS |
| JP2022510014A (ja) * | 2018-12-05 | 2022-01-25 | アテア ファーマシューティカルズ， インコーポレイテッド | Ｃ型肝炎ウイルスの治療のための高活性な合剤 |
| US10874687B1 (en) * | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| AU2022213335A1 (en) * | 2021-01-26 | 2023-07-27 | Atea Pharmaceuticals, Inc. | Advantageous morphic form of at-527 hemi-sulfate salt |
-
2022
- 2022-01-26 AU AU2022213335A patent/AU2022213335A1/en active Pending
- 2022-01-26 BR BR112023014825A patent/BR112023014825A2/pt unknown
- 2022-01-26 MX MX2023008746A patent/MX2023008746A/es unknown
- 2022-01-26 CN CN202280011806.3A patent/CN116744939A/zh active Pending
- 2022-01-26 WO PCT/US2022/013953 patent/WO2022164941A1/en not_active Ceased
- 2022-01-26 EP EP22746553.1A patent/EP4284389A4/en active Pending
- 2022-01-26 TW TW111103408A patent/TW202245806A/zh unknown
- 2022-01-26 KR KR1020237028660A patent/KR20230135635A/ko active Pending
- 2022-01-26 JP JP2023544450A patent/JP2024504392A/ja active Pending
- 2022-01-26 CA CA3173656A patent/CA3173656A1/en active Pending
-
2023
- 2023-07-11 IL IL304402A patent/IL304402A/en unknown
- 2023-07-25 US US18/226,064 patent/US20230365611A1/en active Pending
-
2025
- 2025-10-06 US US19/350,713 patent/US20260035404A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230135635A (ko) | 2023-09-25 |
| JP2024504392A (ja) | 2024-01-31 |
| US20230365611A1 (en) | 2023-11-16 |
| TW202245806A (zh) | 2022-12-01 |
| EP4284389A4 (en) | 2025-04-16 |
| EP4284389A1 (en) | 2023-12-06 |
| AU2022213335A1 (en) | 2023-07-27 |
| WO2022164941A1 (en) | 2022-08-04 |
| CN116744939A (zh) | 2023-09-12 |
| US20260035404A1 (en) | 2026-02-05 |
| IL304402A (en) | 2023-09-01 |
| CA3173656A1 (en) | 2022-08-04 |
| BR112023014825A2 (pt) | 2023-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023008746A (es) | Forma morfica ventajosa de la sal de hemi-sulfato de at-527. | |
| MX2021002321A (es) | Nuevos metodos. | |
| EP4684836A3 (en) | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases | |
| NZ780890A (en) | Pharmaceutical compositions comprising meloxicam | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| MX2020014000A (es) | Formulaciones en lámina que contienen dexmedetomidina y métodos para producirlas. | |
| MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| MX2020012180A (es) | Compuestos biciclicos fusionados utiles como inhibidores de la peptidasa 30 especifica de ubiquitina. | |
| PH12019502201A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| PH12019502095A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| PH12019502559A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| EA201792592A1 (ru) | Фармацевтические препараты, содержащие тенофовир и эмтрицитабин | |
| PH12018501001A1 (en) | Therapeutic compositions for treatment of human immunodeficiency virus | |
| MX381634B (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue. | |
| CR20190531A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| EP3970712A3 (en) | Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof | |
| MX2018011788A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue. | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| MY202884A (en) | Compounds useful in hiv therapy | |
| PH12022550448A1 (en) | Niclosamide delayed-release composition and antiviral use thereof | |
| MX2024004725A (es) | Metodos novedosos. | |
| PH12020552274A1 (en) | Formulations of an axl/mer inhibitor | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| MX380070B (es) | Una composición farmacéutica que comprende amlodipino, valsartán y rosuvastatina. | |
| MX373272B (es) | Terapia de combinacion. |